Anti-CD20 antibodies
US7422739B2 · kind B2 · utility
138Cited by
25References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 25, 2001 |
| Grant date | Sep 9, 2008 |
| Priority date | — |
| Expiry date | May 14, 2024 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/867
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.